Sector News

Fosun Pharma picks up GSK plant in China along with rights to make Epivir generic

July 10, 2019
Life sciences

Even as GlaxoSmithKline has opened its most advanced manufacturing site in Asia, it is selling an older plant in China to Shanghai Fosun Pharmaceutical.

Fosun Pharma announced that it has a deal with GSK to buy its Suzhou pharmaceutical factory in east China near Shanghai for ¥250 million ($36 million), China.org reports. Fosun, among China’s largest drugmakers, said the plant produced revenue of ¥656.1 million ($94.4 million) last year.

The Chinese drugmaker also is getting the rights to produce GSK’s older chronic hepatitis B and HIV drug lamivudine.

Lamivudine is the active ingredient in GSK’s HIV and hepatitis drug Epivir, which GSK now uses in its combo HIV meds. But with the opening of GSK’s new continuous manufacturing facilities at its site in Singapore, it now has the ability to make APIs like lamivudine faster and more inexpensively.

The U.K. drugmaker Monday announced the opening of a $95 million continuous manufacturing complex in Singapore. One part of the operation will make APIs for HIV drugs such as dolutegravir, a combo of Tivicay (dolutegravir, DTG) and Epivir (lamivudine, 3TC).

The manufacturing method puts ingredients through a series of heaters, spinners, extractors and other equipment to achieve an enzymatic result instead of using batches and chemical reactions. The plants are smaller, faster and cheaper, use far less energy and produce far less waste. .

GSK said the first new drug to be manufactured using the enzymatic process will be daprodustat, a new oral treatment for anemia associated with chronic kidney disease. It also is using continuous processing in a part of a pilot plant that makes APIs for clinical trials.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”